DaVita

DaVita EBITDA per Share

The EBITDA per Share of DaVita (DVA) as of Oct 30, 2026 is 30.94 USD. In the previous year, EBITDA per Share was 32.80 USD — a change of -5.67% (lower).

EBITDA per Share

30.94USD

YoY

-5.67%

Last updated:

EBITDA per Share of DaVita is 2025 30.94 USD. EBITDA per Share of DaVita was 2024 32.80 USD. It decreases by -5.67% lower compared to the previous year.

The DaVita EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
12.72 USD
Jan 1, 2019
17.30 USD
Jan 1, 2020
20.05 USD
Jan 1, 2021
23.64 USD
Jan 1, 2022
22.37 USD
Jan 1, 2023
25.31 USD
Jan 1, 2024
32.80 USD
Jan 1, 2025
30.94 USD
The DaVita EBITDA per Share history
YEAREBITDA per ShareYoY
30.94USD-5.67%
32.80USD+29.61%
25.31USD+13.12%
22.37USD-5.36%
23.64USD+17.92%
20.05USD+15.85%
17.30USD+36.09%
12.72USD-0.95%
12.84USD-0.51%
12.90USD+51.78%
8.50USD-23.11%
11.06USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaVita Stock analysis

What does DaVita do? DaVita Inc. is a company headquartered in Denver, Colorado, specializing in the provision and management of outpatient dialysis treatments (renal replacement therapy) and related services. The company was founded in 1999 and has since experienced impressive growth, with a presence in over ten countries worldwide. The history of DaVita traces back to the origin of its business model: outpatient dialysis treatment. This is a form of renal replacement therapy where patients can be treated outside of the hospital, in a dedicated center or even in their own homes. This type of dialysis is less intimidating compared to inpatient treatment in a hospital and can be much more flexible in terms of scheduling. DaVita took this idea and brought it to the market in the US and other countries, where it has proven to be extremely successful. Nowadays, DaVita operates in three main business segments. The first is the patient care segment, which focuses on providing dialysis treatments and related services. Here, DaVita offers outpatient dialysis centers where patients can receive regular treatment. Another important aspect of this segment is patient and family education, integrating them into the treatment process and helping them lead as normal a life as possible. The second core area is the pharmaceutical supply business. DaVita has an extensive network of facilities and suppliers, as well as its own pharmacies where the necessary medications for dialysis patients are manufactured and stored. DaVita also handles billing with insurance and other payment entities to ensure seamless patient care. The third core area of DaVita is the international supply company. Here, DaVita offers its services in over ten countries worldwide, including Mexico, Colombia, Brazil, Saudi Arabia, and Canada. DaVita has steadily expanded its international business in recent years and aims to have a presence in even more countries in the future. But DaVita does not limit itself to these three core areas. The company is also known for its innovative research and development efforts aimed at improving the treatment of kidney disease and developing new technologies. Products offered by DaVita include innovative dialysis devices, advanced care management software, and intelligent sensors for automated patient monitoring. In its over 20-year history, DaVita has overcome many challenges, including regulatory issues, economic fluctuations, and ever-growing competition. Despite these challenges, the company has steadily expanded its position in the industry and established itself as a leading provider of dialysis and related services. DaVita's success is based on a culture of results orientation and a strong commitment to improving patient outcomes. The company understands that each patient has unique needs and that the treatment of kidney disease requires a lifelong commitment. Therefore, DaVita emphasizes individual care and collaboration with patients and their families to ensure optimal care. Overall, DaVita is an innovative company specializing in the provision of dialysis treatments and related services. The company has overcome many challenges in its history and established itself as a leading provider of dialysis and related services. DaVita is committed to improving the quality of life for dialysis patients worldwide and continuously optimizing the treatment of kidney disease. DaVita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaVita stock

EBITDA per Share of DaVita is 30.94 USD in 2025.

EBITDA per Share of DaVita changed from 32.80 USD to 30.94 USD, representing a -5.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share DaVita since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — DaVita

All Key Metrics — DaVita